Conavi Medical increases public offering size in Toronto

Conavi Medical Corp. announced that it is increasing the size of its planned public offering. The company designs and manufactures imaging technologies for minimally invasive heart procedures. The Toronto-based company is now set to offer common shares and may include purchase warrants. The exact number and price of shares are still being negotiated. An updated prospectus was filed on March 20, 2025, with plans to use the funds to further develop its Novasight 3.0 technology, aiming to apply for FDA clearance later this year. Conavi expects the offering will close on or around March 31, 2025, subject to regulatory approvals. The company’s shares will not be offered in the U.S. and have not been registered under U.S. securities laws. The Novasight Hybrid System from Conavi combines two imaging technologies for better visualization of coronary arteries. It has already received various regulatory approvals, including from the FDA. Investors are encouraged to read the prospectus carefully before deciding to invest. Conavi cautioned that forward-looking statements about the company's future may not come to pass due to various risks and uncertainties.